Altered cardiovascular risk pattern of LDL cholesterol in older adults.
Maarten Pieter Rozing, Rudi G J Westendorp
https://pubmed.ncbi.nlm.nih.gov/36413436/Actively Recruiting
Led by Duke University · Updated on 2026-09-01
20000
Participants Needed
106
Research Sites
N/A
Total Duration
Researchers are evaluating the effects of atorvastatin 40 mg daily compared to a matching placebo in adults aged 75 years and older who live in the community and do not have cardiovascular disease or dementia. This large, randomized, placebo-controlled study aims to understand whether statins can reduce death, dementia, persistent disability, mild cognitive impairment, and cardiovascular events in this older population. The study is conducted at about 100 sites across the U.S. and includes both VA and non-VA centers. Participants will be randomly assigned to take either atorvastatin 40 mg or a placebo pill daily for up to 5 years, with an expected median follow-up of about 3.8 years. Study medication will be mailed directly to participants every 90 days. Some participants will have blood samples taken at baseline and again at 3 months to measure lipid levels, and additional physical and cognitive function tests will be performed. Enrollment can occur in person or remotely through telehealth, and community groups are involved in recruitment efforts. During the study, participants will be contacted annually by a central call center to assess cognitive and physical function using phone-based questionnaires. If certain signs are detected, in-person assessments and interviews with informants will be conducted. Researchers will also gather information on cardiovascular events from medical records and national databases. The study will monitor outcomes related to dementia diagnosis and disability over four years, with the total participation lasting up to five years.
CONDITIONS
Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults
P
Pamela Monds
B
Beth Harris
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Duke University
Lead Sponsor
National Institute on Aging (NIA)
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Atorvastatin 40 mg | Placebo | Guideline-Based Statin Therapy |
|---|---|---|---|
| What is it? | A statin medication (atorvastatin 40 mg) taken daily as a cholesterol-lowering drug. | A daily placebo tablet with no active cholesterol-lowering ingredient. | Current clinical guidelines recommend considering high-intensity statin therapy, such as atorvastatin 40–80 mg or rosuvastatin 20–40 mg, to lower cholesterol and reduce cardiovascular risk. |
| Role in the trial | Interventional arm; participants are assigned to receive atorvastatin 40 mg daily. | Comparator arm; participants are assigned to receive placebo for blinded comparison. | Not a trial arm; represents guideline-based care offered outside the trial to similar older adults. |
| Primary use or goal | To determine if daily atorvastatin reduces new cases of dementia and persistent disability in older adults without cardiovascular disease. | Allows measurement of outcomes without active lipid-lowering, for comparison with atorvastatin. | Recommended to lower cholesterol and reduce risk of heart attack and stroke in adults 75 and older at significant cardiovascular risk. |
| How is it given or performed? | Taken once daily by mouth as a tablet for up to 4 years. | Taken once daily by mouth as a matching inactive tablet for up to 4 years. | High-intensity statin (e.g., atorvastatin or rosuvastatin) is prescribed by a clinician and taken by mouth daily; dose and duration are guided by clinical judgement. |
| Evidence status | The benefits of atorvastatin for preventing dementia or disability in older adults without cardiovascular disease are not yet known; this is being studied in the PREVENTABLE trial, with results pending. | Placebo does not lower cholesterol or reduce cardiovascular risk, and is used for comparison only. | Statin use reduces the risk of atherosclerotic cardiovascular disease. For adults over 75 without established disease, evidence for dementia or disability prevention is unclear, so guidelines recommend individualized care. |
| Important limitations | Long-term risks and benefits for dementia or disability prevention are not established; results are still being collected. Study population excludes those with recent heart failure, established dementia, or prior statin intolerance. | Does not provide any preventive therapy; used only as a control. Outcomes reflect the absence of active lipid-lowering intervention. | Guideline recommendations support individualized statin use in adults over 75, but evidence for impact on dementia or physical disability is lacking. Clinical judgment is needed for decision-making. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are assessed to confirm they meet the study requirements before joining the trial.
Screening and enrollment visit
Duration - Up to 5 years
Participants take either atorvastatin 40 mg or a matching placebo pill daily, with medication mailed directly to their home every 90 days.
Annual phone assessments and possible in-person visits if needed
Duration - Up to 5 years
Ongoing monitoring of cognitive and physical health through phone and in-person assessments to track outcomes like dementia and disability.
Annual phone assessments with additional visits as needed
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Maarten Pieter Rozing, Rudi G J Westendorp
https://pubmed.ncbi.nlm.nih.gov/36413436/Jaime Lynn Speiser, Walter T Ambrosius, Nicholas M Pajewski
https://pubmed.ncbi.nlm.nih.gov/37243355/Jacob Joseph, Nicholas M Pajewski, Rowena J Dolor...
https://pubmed.ncbi.nlm.nih.gov/37082807/Duke University
Lead Sponsor
National Institute on Aging (NIA)
Collaborating Sponsor